Why Symptoms and Clinical Signs Often Diverge in oGVHD

One of the most challenging features of oGVHD is the mismatch between symptoms and clinical signs.

Some patients report severe pain, dryness, burning, grittiness, or light sensitivity even when visible findings appear moderate. Others may show clear ocular surface damage but report fewer symptoms than expected. This divergence can be confusing for patients, clinicians, and researchers.

The mismatch does not mean the patient experience is unreliable. It reflects the complexity of ocular surface biology.

Symptoms are shaped by tear-film instability, inflammation, epithelial damage, eyelid friction, environmental exposure, corneal nerves, and central sensory processing. The same clinical finding may feel different from one patient to another. A small epithelial defect may be extremely painful for one person and less symptomatic for another.

Clinical signs also have limitations. Staining, tear production, tear breakup, redness, conjunctival scarring, eyelid findings, and meibomian gland assessment are valuable, but they do not capture every dimension of disease. They may not fully reflect inflammatory activity, nerve dysfunction, treatment burden, or functional impact.

This matters for diagnosis. If care relies only on symptoms, clinically significant surface damage can be missed. If care relies only on visible signs, the patient’s lived burden can be underestimated. oGVHD requires both careful examination and serious attention to patient-reported experience.

This issue also matters in clinical research. Trial design becomes harder when signs and symptoms do not move together. If a therapy improves corneal staining but the patient still has pain, is that a success? If symptoms improve but objective findings remain unchanged, how should that be interpreted? These are not abstract questions. They shape endpoint selection, study design, and regulatory strategy.

The TFOS DEWS II classification report specifically recognizes clinical scenarios in which symptoms may occur without obvious signs, and signs may occur with reduced symptoms. While TFOS DEWS II addresses dry eye disease broadly rather than oGVHD specifically, the principle is relevant to ocular surface disease measurement.

For patients and advocates, this is important because many people with ocular disease have experienced dismissal when test results do not fully explain symptoms. A sophisticated view of oGVHD recognizes that both symptoms and signs are necessary, but neither is sufficient alone.

Better measurement will require integrated assessment: clinical findings, patient-reported outcomes, functional impact, biomarkers, imaging, and longitudinal follow-up.

In oGVHD, the goal is not to choose between what the clinician sees and what the patient feels. The goal is to understand both.

This article is for educational purposes only and is not medical advice.

Sources:

1. Craig JP, Nichols KK, Akpek EK, et al. “TFOS DEWS II Definition and Classification Report.” The Ocular Surface, 2017.
   https://www.tfosdewsreport.org/report-definition_and_classification/48_36/en/
2. Wolffsohn JS, Arita R, Chalmers R, et al. “TFOS DEWS II Diagnostic Methodology Report.” The Ocular Surface, 2017.
   https://www.tfosdewsreport.org/public/images/TFOS_DEWS_II_Diagnostic_method.pdf
3. Jagasia MH, Greinix HT, Arora M, et al. “National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report.” Biology of Blood and Marrow Transplantation, 2015.
   https://pmc.ncbi.nlm.nih.gov/articles/PMC4329079/